Login to Your Account

Proclara lands $47M series E, focuses on Alzheimer's end 'GAIM'

By Marie Powers
News Editor

Wednesday, September 7, 2016

Neurophage Pharmaceuticals Inc. re-branded itself as Proclara Biosciences as it hauled in a $47 million series E and moved lead candidate, NPT088, into a phase Ib trial in Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription